Synthon (rights of glatiramer acetate) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Synthon (rights of glatiramer acetate) General Information

Description

The commercialization rights of glatiramer acetate in the United States. It is a potential generic version of the originator medicine Copaxone® for the treatment of relapsing remitting multiple sclerosis (RRMS).

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • P.O. Box 110487
  • Research Triangle Park
  • Durham, NC 27709
  • United States
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Other Business Products and Services
Acquirer
Pfizer
Corporate Office
  • P.O. Box 110487
  • Research Triangle Park
  • Durham, NC 27709
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Synthon (rights of glatiramer acetate) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Synthon (rights of glatiramer acetate)‘s full profile, request access.

Request a free trial

Synthon (rights of glatiramer acetate) FAQs

  • Where is Synthon (rights of glatiramer acetate) headquartered?

    Synthon (rights of glatiramer acetate) is headquartered in Durham, NC.

  • What industry is Synthon (rights of glatiramer acetate) in?

    Synthon (rights of glatiramer acetate)’s primary industry is Buildings and Property.

  • Is Synthon (rights of glatiramer acetate) a private or public company?

    Synthon (rights of glatiramer acetate) is a Private company.

  • What is Synthon (rights of glatiramer acetate)’s current revenue?

    The current revenue for Synthon (rights of glatiramer acetate) is 000000.

  • When was Synthon (rights of glatiramer acetate) acquired?

    Synthon (rights of glatiramer acetate) was acquired on 03-Aug-2015.

  • Who acquired Synthon (rights of glatiramer acetate)?

    Synthon (rights of glatiramer acetate) was acquired by Pfizer.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »